Simvastatin reduces platelet-endocardium adhesion in atrial fibrillation

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 588-595

  Chello, Massimo ^a   Spadaccio, Cristiano ^a   Patti, Giuseppe ^a   Lusini, Mario ^a   Barbato, Raffaele ^a   Goffredo, Costanza ^a   Di Sciascio, Germano ^a   Covino, Elvio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Atrial fibrillation; CD40; Platelets; Statin

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; FIBRINOGEN RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; SIMVASTATIN;

ADULT; AGED; ARTICLE; CARDIOPULMONARY BYPASS; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; ENDOCARDIUM; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HEART RIGHT ATRIUM; HEART SURGERY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK REDUCTION; SINUS RHYTHM; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; UNIVERSITY HOSPITAL;

AGED; ANTIGENS, CD40; ATRIAL FIBRILLATION; ATRIAL FUNCTION, RIGHT; CASE-CONTROL STUDIES; CD40 LIGAND; ENDOCARDIUM; FEMALE; HEART ATRIA; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MIDDLE AGED; PLATELET ADHESIVENESS; SIMVASTATIN;

EID: 40949157019     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.08.021     Document Type: Article

References (23)

1. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke 22 (1991) 983-988
2. Hart G.R., and Halperin J.L. Atrial fibrillation and stroke concepts and controversies. Stroke 32 (2001) 803-808
3. Lip G.Y.H., Lip P.L., Zarifis J., et al. Fibrin d-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Circulation 94 (1996) 425-431
4. Yamashita T., Sekiguchi A., Iwasaki Y., et al. Thrombomodulin and tissue factor pathway inhibitor in endocardium of rapidly paced rat atria. Circulation 108 (2003) 2450-2452
5. Kamath S., Blann A.D., Chin B.S.P., et al. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy. Eur Heart J 23 (2002) 1788-1795
6. Morillo C.A., Klein G.J., Jones D.L., and Guiraudon C.M. Chronic rapid atrial pacing. Structural, functional, and electrophysiological Simon P characteristics of a new model of sustained atrial fibrillation. Circulation 91 (1995) 1588-1595
7. Blanco M., Rodriguez-Yanez M., Sobrino T., Leira R., and Castillo J. Platelets, inflammation, and atherothrombotic neurovascular disease: the role of endothelial dysfunction. Cerebrovasc Dis 20 2 (2005) 32-39
8. Freedman J.E. CD40-CD40L and platelet function: beyond hemostasis. Circ Res 92 (2003) 944-946
9. Inwald D.P., McDowall A., Peters M.J., Callard R.E., and Klein N.J. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res 92 (2003) 1041-1048
10. Phipps R.P. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci USA 97 (2000) 6930-6932
11. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391 (1998) 591-594
12. Aukrust P., Damas J.K., and Solum N.O. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?. JACC 16 (2004) 2326-2328
13. Cipollone F., Mezzetti A., Porreca E., et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 106 (2002) 399-402
14. Mulhaupt F., Matter C.M., Kwak B.R., et al. Statin (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 59 (2003) 755-766
15. Wagner A.H., Gebauer M., Güldenzoph B., and Hecker M. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol 22 (2002) 1784-1789
16. Mieszczak C., and Winther K. Does warfarin enhance platelet activity?. Thromb Res 84 (1996) 285-287
17. Sanguigni V., Pignatelli P., Lenti L., et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation 111 (2005) 412-419
18. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
19. Garlichs C.D., John S., Schmeisser A., et al. Upregulation of CD40 and CD40 ligand (CD154) in patients with moderate hypercholesterolemia. Circulation 104 (2001) 2395-2400
20. Lefer A.M., Scalia R., and Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concept for cardiovascular disease. Cardiovasc Res 49 (2001) 281-287
21. Miller S.J. Emerging mechanisms for secondary cardioprotective effects of statins. Cardiovasc Res 52 (2001) 5-7
22. Chello M., Patti G., Candura D., et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 34 (2006) 660-667
23. Lip G.Y., Patel J.V., Hughes E., and Hart R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 38 (2007) 1129-1137